ArticleJournal of the National Comprehensive Cancer Network : JNCCN2008
Novel systemic therapies for small cell lung cancer.
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Novel oncolytic viral therapies in patients with thoracic malignancies.Oncolytic virotherapy · 2017Review
- Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.Molecular cancer therapeutics · 2016Article
- Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer.Molecular & cellular proteomics : MCP · 2014Article
- Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- The development of targeted therapy in small cell lung cancer.Journal of thoracic disease · 2013Article
- Nicotinic acetylcholine receptors mediate lung cancer growth.Frontiers in physiology · 2013Article
- Staging and imaging of small cell lung cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2012Review
- Article
- A crucial requirement for Hedgehog signaling in small cell lung cancer.Nature medicine · 2011Article
- Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.Nature reviews. Clinical oncology · 2011Review
- Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.Cancer research · 2010Article
- Management of small-cell lung cancer: incremental changes but hope for the future.Oncology (Williston Park, N.Y.) · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
A diagnosis of small cell lung cancer (SCLC) today confers essentially the same terrible prognosis that it did 25 years ago, when common use of cisplatin-based chemotherapy began for this disease. In contrast to past decades of research on many other solid tumors, studies of combination chemotherapy using later generation cytotoxics and targeted kinase inhibitors have not had a significant impact on standard care for SCLC. The past few years have seen suggestions of incrementally improved outcomes using standard cytotoxics, including cisplatin-based combination studies of irinotecan and amrubicin by Japanese research consortia. Confirmatory phase III studies of these agents are ongoing in the United States. Antiangiogenic strategies are also of primary interest and are in late-phase testing. Several novel therapeutics, including high-potency small molecule inhibitors of Bcl-2 and the Hedgehog signaling pathway, and a recently discovered replication-competent picornavirus, have shown remarkable activity against SCLC in preclinical models and are currently in simultaneous phase I clinical development. Novel therapeutic approaches based on advances in understanding of the biology of SCLC have the potential to radically change the outlook for patients with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.